Flosequinan

A vasodilator with positive inotropic activity

William J. Corin, E. Scott Monrad, Joel A. Strom, Sylvana Giustino, Edmund S. Sonnenblick, Thierry LeJemtel

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Flosequinan is an oral arterial and venous vasodilator that is currently under investigation for the treatment of congestive heart failure. The effects of flosequinan on ventricular performance and myocardial contractility were studied in 10 patients with severe congestive heart failure during right and left cardiac catheterization. Sixty minutes after a 100 mg oral dose of flosequinan, the peak rate of rise in left ventricular pressure ( dP dt) increased from 940 ± 180 to 1050 ± 240 mm Hg/sec (p < 0.05), while left ventricular end-diastolic pressure decreased from 32 ± 5 to 26 ± 8 mm Hg (p < 0.05), and cardiac index increased (2.1 ± 0.4 to 2.3 ± 0.5 L/min/m2, (p < 0.05). The mean pulmonary artery pressure and vascular resistance decreased from 40 ± 8 to 33 ± 12 mm Hg (p < 0.05) and from 330 ± 240 to 290 ± 170 dyne-sec/cm5 (p < 0.05), respectively. Heart rate, mean aortic pressure, right atrial pressure, systemic vascular resistance, and serum norepinephrine levels did not change significantly. The increase in left ventricular peak dP dt that was concomitant with a decrease in left ventricular end-diastolic pressure, and no change in systemic arterial pressure or sympathetic tone, argue for a direct positive inotropic effect of flosequinan.

Original languageEnglish (US)
Pages (from-to)537-540
Number of pages4
JournalAmerican Heart Journal
Volume121
Issue number2 PART 1
DOIs
StatePublished - 1991

Fingerprint

flosequinan
Vasodilator Agents
Vascular Resistance
Arterial Pressure
Heart Failure
Blood Pressure
Atrial Pressure
Ventricular Pressure
Cardiac Catheterization
Pulmonary Artery
Norepinephrine
Heart Rate
Pressure
Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Corin, W. J., Monrad, E. S., Strom, J. A., Giustino, S., Sonnenblick, E. S., & LeJemtel, T. (1991). Flosequinan: A vasodilator with positive inotropic activity. American Heart Journal, 121(2 PART 1), 537-540. https://doi.org/10.1016/0002-8703(91)90723-U

Flosequinan : A vasodilator with positive inotropic activity. / Corin, William J.; Monrad, E. Scott; Strom, Joel A.; Giustino, Sylvana; Sonnenblick, Edmund S.; LeJemtel, Thierry.

In: American Heart Journal, Vol. 121, No. 2 PART 1, 1991, p. 537-540.

Research output: Contribution to journalArticle

Corin, WJ, Monrad, ES, Strom, JA, Giustino, S, Sonnenblick, ES & LeJemtel, T 1991, 'Flosequinan: A vasodilator with positive inotropic activity', American Heart Journal, vol. 121, no. 2 PART 1, pp. 537-540. https://doi.org/10.1016/0002-8703(91)90723-U
Corin WJ, Monrad ES, Strom JA, Giustino S, Sonnenblick ES, LeJemtel T. Flosequinan: A vasodilator with positive inotropic activity. American Heart Journal. 1991;121(2 PART 1):537-540. https://doi.org/10.1016/0002-8703(91)90723-U
Corin, William J. ; Monrad, E. Scott ; Strom, Joel A. ; Giustino, Sylvana ; Sonnenblick, Edmund S. ; LeJemtel, Thierry. / Flosequinan : A vasodilator with positive inotropic activity. In: American Heart Journal. 1991 ; Vol. 121, No. 2 PART 1. pp. 537-540.
@article{d011364f8a254e88a45bb2e3ccded6cc,
title = "Flosequinan: A vasodilator with positive inotropic activity",
abstract = "Flosequinan is an oral arterial and venous vasodilator that is currently under investigation for the treatment of congestive heart failure. The effects of flosequinan on ventricular performance and myocardial contractility were studied in 10 patients with severe congestive heart failure during right and left cardiac catheterization. Sixty minutes after a 100 mg oral dose of flosequinan, the peak rate of rise in left ventricular pressure ( dP dt) increased from 940 ± 180 to 1050 ± 240 mm Hg/sec (p < 0.05), while left ventricular end-diastolic pressure decreased from 32 ± 5 to 26 ± 8 mm Hg (p < 0.05), and cardiac index increased (2.1 ± 0.4 to 2.3 ± 0.5 L/min/m2, (p < 0.05). The mean pulmonary artery pressure and vascular resistance decreased from 40 ± 8 to 33 ± 12 mm Hg (p < 0.05) and from 330 ± 240 to 290 ± 170 dyne-sec/cm5 (p < 0.05), respectively. Heart rate, mean aortic pressure, right atrial pressure, systemic vascular resistance, and serum norepinephrine levels did not change significantly. The increase in left ventricular peak dP dt that was concomitant with a decrease in left ventricular end-diastolic pressure, and no change in systemic arterial pressure or sympathetic tone, argue for a direct positive inotropic effect of flosequinan.",
author = "Corin, {William J.} and Monrad, {E. Scott} and Strom, {Joel A.} and Sylvana Giustino and Sonnenblick, {Edmund S.} and Thierry LeJemtel",
year = "1991",
doi = "10.1016/0002-8703(91)90723-U",
language = "English (US)",
volume = "121",
pages = "537--540",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2 PART 1",

}

TY - JOUR

T1 - Flosequinan

T2 - A vasodilator with positive inotropic activity

AU - Corin, William J.

AU - Monrad, E. Scott

AU - Strom, Joel A.

AU - Giustino, Sylvana

AU - Sonnenblick, Edmund S.

AU - LeJemtel, Thierry

PY - 1991

Y1 - 1991

N2 - Flosequinan is an oral arterial and venous vasodilator that is currently under investigation for the treatment of congestive heart failure. The effects of flosequinan on ventricular performance and myocardial contractility were studied in 10 patients with severe congestive heart failure during right and left cardiac catheterization. Sixty minutes after a 100 mg oral dose of flosequinan, the peak rate of rise in left ventricular pressure ( dP dt) increased from 940 ± 180 to 1050 ± 240 mm Hg/sec (p < 0.05), while left ventricular end-diastolic pressure decreased from 32 ± 5 to 26 ± 8 mm Hg (p < 0.05), and cardiac index increased (2.1 ± 0.4 to 2.3 ± 0.5 L/min/m2, (p < 0.05). The mean pulmonary artery pressure and vascular resistance decreased from 40 ± 8 to 33 ± 12 mm Hg (p < 0.05) and from 330 ± 240 to 290 ± 170 dyne-sec/cm5 (p < 0.05), respectively. Heart rate, mean aortic pressure, right atrial pressure, systemic vascular resistance, and serum norepinephrine levels did not change significantly. The increase in left ventricular peak dP dt that was concomitant with a decrease in left ventricular end-diastolic pressure, and no change in systemic arterial pressure or sympathetic tone, argue for a direct positive inotropic effect of flosequinan.

AB - Flosequinan is an oral arterial and venous vasodilator that is currently under investigation for the treatment of congestive heart failure. The effects of flosequinan on ventricular performance and myocardial contractility were studied in 10 patients with severe congestive heart failure during right and left cardiac catheterization. Sixty minutes after a 100 mg oral dose of flosequinan, the peak rate of rise in left ventricular pressure ( dP dt) increased from 940 ± 180 to 1050 ± 240 mm Hg/sec (p < 0.05), while left ventricular end-diastolic pressure decreased from 32 ± 5 to 26 ± 8 mm Hg (p < 0.05), and cardiac index increased (2.1 ± 0.4 to 2.3 ± 0.5 L/min/m2, (p < 0.05). The mean pulmonary artery pressure and vascular resistance decreased from 40 ± 8 to 33 ± 12 mm Hg (p < 0.05) and from 330 ± 240 to 290 ± 170 dyne-sec/cm5 (p < 0.05), respectively. Heart rate, mean aortic pressure, right atrial pressure, systemic vascular resistance, and serum norepinephrine levels did not change significantly. The increase in left ventricular peak dP dt that was concomitant with a decrease in left ventricular end-diastolic pressure, and no change in systemic arterial pressure or sympathetic tone, argue for a direct positive inotropic effect of flosequinan.

UR - http://www.scopus.com/inward/record.url?scp=0026078027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026078027&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(91)90723-U

DO - 10.1016/0002-8703(91)90723-U

M3 - Article

VL - 121

SP - 537

EP - 540

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2 PART 1

ER -